+31.3%
ABNB vs MRNA
+153.9%
-122.6%
-37.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.4% | -2.2% | +0.8% | -1.3% |
| 7D | -8.8% | -12.7% | +3.9% | -8.1% |
| 30D | -1.9% | -20.7% | +18.8% | -0.8% |
| 3M | -7.9% | +46.3% | -54.2% | -10.1% |
| 6M | +25.7% | +305.2% | -279.6% | +7.5% |
| YTD | +25.5% | +561.2% | -535.7% | -1.1% |
| 1Y | +52.7% | +772.1% | -719.4% | +15.1% |
| 3Y | +31.3% | +147.0% | -115.6% | +3.9% |
| All | +31.3% | +153.9% | -122.6% | +3.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling